CA2437812A1 - Compositions and methods for modulation of vascular structure and/or function - Google Patents

Compositions and methods for modulation of vascular structure and/or function Download PDF

Info

Publication number
CA2437812A1
CA2437812A1 CA 2437812 CA2437812A CA2437812A1 CA 2437812 A1 CA2437812 A1 CA 2437812A1 CA 2437812 CA2437812 CA 2437812 CA 2437812 A CA2437812 A CA 2437812A CA 2437812 A1 CA2437812 A1 CA 2437812A1
Authority
CA
Canada
Prior art keywords
beta
fwdarw
acetylglucosamine
polymers
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2437812
Other languages
French (fr)
Other versions
CA2437812C (en
Inventor
John N. Vournakis
Sergio Finkeilsztein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2437812A1 publication Critical patent/CA2437812A1/en
Application granted granted Critical
Publication of CA2437812C publication Critical patent/CA2437812C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Abstract

The present invention relates to compositions comprising semi-crystalline .beta.-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration- dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a .beta.-1-4 conformation.

Claims (38)

1. A method for achieving at least a transient, localized, modulation of vascular structure and/or function, comprising:
topically administering to a patient in need of said modulation, a sufficient amount of material comprising semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymers, wherein said administering induces at least a transient, localized physiological response selected from the group consisting of stimulation of endothelia-1 release, vasoconstriction, and reduction in blood flow out of a breached vessel, whereby the patient experiences at least a transient, localized modulation of vascular structure and/or function.
2. The method of claim 1, wherein the physiological response comprises stimulation of endothelia-1 release.
3. The method of claim 2, wherein the endothelia-1 is released from vascular endothelial cells.
4. The method of claim 1, wherein the physiological response comprises vasoconstriction.
5. The method of claim 1, wherein the physiological response comprises reduction in blood flow out of a breached vessel.
6. The method of claim 1, wherein the poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 50 to about 150,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation, and said polymer has a molecular weight of about 10,000 daltons to about 30 million daltons.
7. The method of claim 6, wherein the poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 50 to about 50,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation, and said polymer has a molecular weight of about 10,000 daltons to about 10 million daltons.
8. The method of claim 7, wherein the poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 50 to about 10,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation, and said polymer has a molecular weight of about 10,000 daltons to about 2 million daltons.
9. The method of claim 8, wherein the poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 50 to about 4,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation, and said polymer has a molecular weight of about 10,000 daltons to about 800,000 daltons.
10. The method of claim 6, wherein the semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises at least one N-acetylglucosamine monosaccharide that is deacetylated, and wherein at least 40% of said N-acetylglucosamine monosaccharides are acetylated.
11. The method of claim 1, wherein the patient is a human.
12. The method of claim 1, wherein the material is in the form of a gel, sponge, film, membrane, foam, spray, emulsion, suspension, or solution.
13. The method of claim 1, wherein the material is applied directly to a blood vessel.
14. The method of claim 1, wherein the vascular structure is a blood vessel selected from the group consisting of capillary, vein, and artery.
15. The method of claim 14, wherein the blood vessel is a breached blood vessel.
16. The method of claim 15, whereby the patient experiences cessation of bleeding.
17. The method of claim 1, wherein the extent of the transient, localized modulation of vascular structure and/or function is substantially proportional to the amount of semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine administered.
18. A biodegradable, non-barrier-forming material comprising semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymers comprising about 50 to about 150,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation, and having a molecular weight of about 10,000 daltons to about 30 million daltons.
19. The material of claim 18, wherein the semi-crystalline poly .beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 54 to about 50,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation and has a molecular weight of about 10,000 daltons to about 14 million daltons.
20. The material of claim 18, wherein the semi-crystalline poly .beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 50 to about 10,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation and has a molecular weight of about 10,000 daltons to about 2 million daltons.
21. The material of claim 18, wherein the semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises about 54 to about 4,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation and has a molecular weight of about 10,000 daltons to about 800,000 daltons.
22. The material of claim 18, wherein the semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymer comprises at least one N-acetylglucosamine monosaccharide that is deacetylated, and wherein at least 40% of said N-acetylglucosamine monosaccharides are acetylated.
23. The material of claim 18, wherein the material is a gel, sponge, film, membrane, foam, spray, emulsion, suspension, or solution.
24. A method for treating a patient having a vascular disorder, comprising:
topically administering to a patient in need of such treatment, a sufficient amount of material comprising semi-crystalline poly .beta.-1.fwdarw.4 N-acetylglucosamine polymers, wherein said administering induces at least a transient, localized physiological response selected from the group consisting of stimulation of endothelin-1 release, vasoconstriction, and reduction in blood flow out of a breached vessel, whereby the patient experiences at least a transient, localized modulation of vascular structure and/or function, whereby said administering ameliorates said vascular condition.
25. The method of claim 24, wherein the vascular disorder is selected from the group consisting of menorrhagia, cerebral aneurysm, abdominal aneurysm, uterine fibroid lesion, and blood vessel puncture.
26. The method of claim 1, wherein said polymers are substantially free of protein.
27. The method of claim 1, wherein said polymers are substantially free of organic contaminants.
28. The method of claim 1, wherein said polymers are substantially free of inorganic contaminants.
29. The biodegradable, non-barrier forming material of claim 18, wherein said polymers are substantially free of protein.
30. The biodegradable, non-barrier forming material of claim 18, wherein said polymers are substantially free of organic contaminants.
31. The biodegradable, non-barrier forming material of claim 18, wherein said polymers are substantially free of inorganic contaminants.
32. The method of claim 24, wherein said polymers are substantially free of protein.
33. The method of claim 24, wherein said polymers are substantially free of organic contaminants.
34. The method of claim 24, wherein said polymers are substantially free of inorganic contaminants.
35. A pharmaceutically-acceptable composition comprising a therapeutically effective amount of a biodegradable, non-barrier-forming material comprising semi-crystalline poly-.beta.-1.fwdarw.4 N-acetylglucosamine polymers comprising about 50 to about 150,000 N-acetylglucosamine monosaccharides covalently attached in a .beta.-1.fwdarw.4 conformation, and having a molecular weight of about 10,000 daltons to about 30 million daltons.
36. The pharmaceutical composition of claim 34, wherein said polymers are substantially free of protein.
37. The pharmaceutical composition of claim 34, wherein said polymers are substantially free of organic contaminants.
38. The pharmaceutical composition of claim 34, wherein said polymers are substantially free of inorganic contaminants.
CA 2437812 2001-02-12 2002-02-08 Compositions and methods for modulation of vascular structure and/or function Expired - Lifetime CA2437812C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/781,182 2001-02-12
US09/781,182 US7041657B2 (en) 2001-02-12 2001-02-12 Compositions and methods for modulation of vascular structure and/or function
PCT/US2002/003792 WO2002063961A1 (en) 2001-02-12 2002-02-08 Composition and methods for modulation of vascular structure and/or function

Publications (2)

Publication Number Publication Date
CA2437812A1 true CA2437812A1 (en) 2002-08-22
CA2437812C CA2437812C (en) 2012-08-28

Family

ID=25121948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2437812 Expired - Lifetime CA2437812C (en) 2001-02-12 2002-02-08 Compositions and methods for modulation of vascular structure and/or function

Country Status (12)

Country Link
US (7) US7041657B2 (en)
EP (2) EP2468094B1 (en)
JP (4) JP5303088B2 (en)
AU (3) AU2002306455B2 (en)
CA (1) CA2437812C (en)
DK (2) DK2468094T3 (en)
ES (2) ES2456695T3 (en)
HK (1) HK1172504A1 (en)
IL (2) IL157327A0 (en)
MX (1) MXPA03007176A (en)
NZ (1) NZ527872A (en)
WO (1) WO2002063961A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US7041657B2 (en) * 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Hemostatic compositions and uses therefor
US7285266B2 (en) 2003-02-24 2007-10-23 Marine Polymer Technologies, Inc. Cell-polymer fiber compositions and uses thereof
US8613772B2 (en) * 2003-04-21 2013-12-24 Rsb Spine Llc Lateral mount implant device
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
US7785615B2 (en) * 2004-05-28 2010-08-31 Cordis Corporation Biodegradable medical implant with encapsulated buffering agent
US7803182B2 (en) * 2004-05-28 2010-09-28 Cordis Corporation Biodegradable vascular device with buffering agent
US20070031468A1 (en) * 2005-08-04 2007-02-08 Endomedix, Inc. Modified chitosan for vascular embolization
US20070031467A1 (en) * 2005-08-04 2007-02-08 Abrahams John M Composition and method for vascular embolization
US20080075657A1 (en) * 2006-04-18 2008-03-27 Abrahams John M Biopolymer system for tissue sealing
US7854923B2 (en) 2006-04-18 2010-12-21 Endomedix, Inc. Biopolymer system for tissue sealing
US20090010982A1 (en) * 2006-04-18 2009-01-08 Endomedix, Inc. Biocompatible adherent sheet for tissue sealing
US20070243130A1 (en) * 2006-04-18 2007-10-18 Weiliam Chen Biopolymer system for tissue sealing
EP2121048B9 (en) 2007-02-19 2016-02-24 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
US8932560B2 (en) 2007-09-04 2015-01-13 University of Maryland, College Parke Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
US9931377B2 (en) 2007-06-27 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell expressing complexes of IL-15 and IL-15Ralpha
US8486033B2 (en) 2007-07-18 2013-07-16 Marine Polymer Technologies, Inc. Application of polymeric materials to screens to facilitate hemostasis and wound healing
US20130096518A1 (en) 2007-12-06 2013-04-18 Smith & Nephew Plc Wound filling apparatuses and methods
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
CA2702604C (en) 2008-09-22 2013-12-03 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
US9278233B2 (en) * 2008-12-04 2016-03-08 Biochemics, Inc. Methods and compositions for tattoo removal
EP2498820B1 (en) 2009-11-13 2019-01-09 University of Maryland, College Park Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
WO2012142581A1 (en) 2011-04-15 2012-10-18 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acety glucosamine nanofibers
CA2914610C (en) 2013-03-13 2022-08-02 University Of Maryland Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
WO2014165302A1 (en) 2013-03-14 2014-10-09 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
US10517988B1 (en) 2018-11-19 2019-12-31 Endomedix, Inc. Methods and compositions for achieving hemostasis and stable blood clot formation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585559A (en) * 1897-06-29 Piano-hammer
US3232836A (en) * 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3903268A (en) * 1968-02-12 1975-09-02 Lescarden Ltd Chitin and chitin derivatives for promoting wound healing
US3632754A (en) * 1968-02-12 1972-01-04 Lescarden Ltd Use of chitin for promoting wound healing
US3911116A (en) * 1970-04-13 1975-10-07 Leslie L Balassa Process for promoting wound healing with chitin derivatives
US3989535A (en) * 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
JPS61240963A (en) * 1985-04-18 1986-10-27 ユニチカ株式会社 Wound covering protective material
JPH0813746B2 (en) * 1987-02-27 1996-02-14 ユニチカ株式会社 Hemostatic agent
CA2004802A1 (en) 1988-12-07 1990-06-07 Christopher R. Bentley Formulations for treating slow and non-healing wounds
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
CA2059380A1 (en) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
US5219749A (en) 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
US5443481A (en) 1992-07-27 1995-08-22 Lee; Benjamin I. Methods and device for percutaneous sealing of arterial puncture sites
GB9305464D0 (en) * 1993-03-17 1993-05-05 Logax Limited Document file
CA2175203A1 (en) * 1993-11-03 1995-05-11 Thaddeus P. Pruss Hemostatic patch
US5437292A (en) * 1993-11-19 1995-08-01 Bioseal, Llc Method for sealing blood vessel puncture sites
US5846952A (en) 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5635493A (en) * 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5622834A (en) 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
WO1995022316A1 (en) * 1994-02-17 1995-08-24 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
WO1995032671A1 (en) * 1994-06-01 1995-12-07 Perclose, Inc. Method and device for providing vascular hemostasis
JPH0853368A (en) * 1994-08-09 1996-02-27 Kyoto Yakuhin Kogyo Kk Ointment preparation
US5814066A (en) * 1994-12-23 1998-09-29 The University Of Virginia Patent Foundation Reduction of femoral arterial bleeding post catheterization using percutaneous application of fibrin sealant
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
WO1996023523A1 (en) * 1995-02-03 1996-08-08 Korea Institute Of Science And Technology Novel hemostatic composition
AU5917896A (en) 1995-06-06 1996-12-24 Marine Polymer Technologies, Inc. Poly-beta-1-4-N-acetylglucosamine
JPH09169653A (en) * 1995-12-22 1997-06-30 Unitika Ltd Chitin-based hemostatic agent
JPH09169654A (en) * 1995-12-22 1997-06-30 Unitika Ltd Hemostatic agent
US5728132A (en) * 1996-04-08 1998-03-17 Tricardia, L.L.C. Self-sealing vascular access device
JPH09291036A (en) * 1996-04-26 1997-11-11 San Five Kk Powdery chitin therapeutic agent for wound
JPH09328432A (en) * 1996-06-06 1997-12-22 Unitika Ltd Spraying agent
JPH1075998A (en) * 1996-09-05 1998-03-24 Unitika Ltd Cotton-like wound protective material
US5855559A (en) * 1997-02-14 1999-01-05 Tricardia, Inc. Hemostatic agent delivery device having built-in pressure sensor
US6193670B1 (en) * 1997-02-14 2001-02-27 Tricardia, Llc Hemostatic agent delivery device having built-in pressure sensor
JPH10295699A (en) * 1997-04-24 1998-11-10 Clinical Supply:Kk Hemostasis implement
US6033427A (en) * 1998-01-07 2000-03-07 Lee; Benjamin I. Method and device for percutaneous sealing of internal puncture sites
US6056970A (en) * 1998-05-07 2000-05-02 Genzyme Corporation Compositions comprising hemostatic compounds and bioabsorbable polymers
US6334865B1 (en) * 1998-08-04 2002-01-01 Fusion Medical Technologies, Inc. Percutaneous tissue track closure assembly and method
US6613070B2 (en) * 1998-08-04 2003-09-02 Baxter International Inc. System and method for sealing vascular penetrations with hemostatic gels
US20020197302A1 (en) * 1998-11-12 2002-12-26 Cochrum Kent C. Hemostatic polymer useful for rapid blood coagulation and hemostasis
US6361551B1 (en) * 1998-12-11 2002-03-26 C. R. Bard, Inc. Collagen hemostatic fibers
JP4159682B2 (en) * 1998-12-22 2008-10-01 株式会社クラレ Hemostatic material
US7041657B2 (en) * 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US6693188B2 (en) * 2001-08-08 2004-02-17 Cargill Incorporated N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine
US7371403B2 (en) * 2002-06-14 2008-05-13 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
EP1587424A4 (en) * 2002-12-31 2012-01-25 Marinepolymer Tech Inc Hemostatic compositions and uses therefor
US7285266B2 (en) * 2003-02-24 2007-10-23 Marine Polymer Technologies, Inc. Cell-polymer fiber compositions and uses thereof
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
EP2121048B9 (en) 2007-02-19 2016-02-24 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens

Also Published As

Publication number Publication date
JP2004526705A (en) 2004-09-02
US20020019367A1 (en) 2002-02-14
US20100323986A1 (en) 2010-12-23
US20090318383A1 (en) 2009-12-24
MXPA03007176A (en) 2005-02-14
IL157327A0 (en) 2004-02-19
IL157327A (en) 2010-12-30
DK2468094T3 (en) 2014-07-21
CA2437812C (en) 2012-08-28
JP2014148517A (en) 2014-08-21
US8859528B2 (en) 2014-10-14
JP5945293B2 (en) 2016-07-05
JP2010265285A (en) 2010-11-25
JP5543861B2 (en) 2014-07-09
JP2016053067A (en) 2016-04-14
EP2468094B1 (en) 2014-04-16
US20030078234A1 (en) 2003-04-24
AU2011200400B2 (en) 2013-07-04
AU2007251899B2 (en) 2011-01-27
WO2002063961A1 (en) 2002-08-22
JP5303088B2 (en) 2013-10-02
US7041657B2 (en) 2006-05-09
AU2007251899A1 (en) 2008-01-24
EP1365651B1 (en) 2014-01-08
EP1365651A4 (en) 2009-02-25
US8481512B2 (en) 2013-07-09
ES2456695T3 (en) 2014-04-23
EP2468094A1 (en) 2012-06-27
DK1365651T3 (en) 2014-03-31
AU2002306455B2 (en) 2007-12-13
ES2477316T3 (en) 2014-07-16
WO2002063961B1 (en) 2003-03-06
AU2011200400A1 (en) 2011-02-24
US20130288999A1 (en) 2013-10-31
EP1365651A1 (en) 2003-12-03
US20070072826A1 (en) 2007-03-29
US20150118281A1 (en) 2015-04-30
NZ527872A (en) 2005-07-29
US7115588B2 (en) 2006-10-03
HK1172504A1 (en) 2013-04-26

Similar Documents

Publication Publication Date Title
CA2437812A1 (en) Compositions and methods for modulation of vascular structure and/or function
Shah et al. Biopolymer-based biomaterials for accelerated diabetic wound healing: A critical review
EP3659631B1 (en) Wound dressing comprising hyaluronic acid-calcium and polylysine and manufacturing method therefor
Sankar et al. Clinical use of the self-assembling peptide RADA16: a review of current and future trends in biomedicine
US20190247306A1 (en) Articles and methods of treating vascular conditions
ES2384519T3 (en) Hemostatic agent for topical and internal use
Gopalakrishnan et al. Ellagic acid encapsulated chitosan nanoparticles as anti-hemorrhagic agent
AU2011200046B2 (en) Vascular access preservation in hemodialysis patients
JP2018183611A (en) In-situ cross-linkable polymeric compositions and methods thereof
CA2712527C (en) Chitosan gel for dermatological use, production method and use of same
CN101583348B (en) Formation of medically useful gels comprising microporous particles and methods of use
US20180036338A1 (en) Flowable hemostatic composition
US20050123588A1 (en) Deployable multifunctional hemostatic agent
KR101678241B1 (en) Preparations based on fibrinogen and sulfated polysaccharides
CN101485897A (en) Biocompatible hemostatic, antiblocking, healing-promoting and surgical wound-closing modified starch material
KR20000022287A (en) Use of oxidized cellulose and complexes thereof for chronic wound healing
BRPI0618216A2 (en) polycation-polyion complexes, compositions and methods of use thereof
CA2529717A1 (en) Deployable hemostatic agent
CA2341998A1 (en) Anti-emetic, anti-motion sustained release drug delivery system,
HUT64479A (en) Process for preparing a pharmaceutical composition containing growth factors and polyelectrolyte
EP1404281B1 (en) Pharmaceutical compositions of topic use, applied in treatment of skin and/or mucous injuries; use of compositions in treatment of skin and/or mucous injuries and use of compounds in treatment of skin and/or mucous injuries
JP5646507B2 (en) Hyaluronic acid-containing composition for treating wounds, scars, and post-surgical adhesion formation
Kushwaha et al. Biopolymers as topical haemostatic agents: current trends and technologies
CN106562953B (en) Application, drug and process for preparing medicine of the hydroxyl radical carthamin yellow carthamus A in the drug of preparation treatment diabetic foot ulcer
Peper et al. Pigskin as a topical hemostat in arterial, liver, and splenic injuries

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220208

MKEX Expiry

Effective date: 20220208